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Abstract 
The loss of melanocytes in vitiligo is mainly attributed to defective autoimmune mechanisms and 
lately autoinflammatory mediators have become more emphasized. Among these, a number of class II 
cytokines and their receptors have displayed altered expression patterns in vitiligo. Thus, we selected 
30 SNPs from the regions of respective genes to be genotyped in Estonian case-control sample (109 
and 238 individuals, respectively). For more precise analyses, patients were divided into subgroups 
based on vitiligo progression activity, age of onset, sex, occurrence of vitiligo among relatives, extent 
of depigmented areas, appearance of Köbner’s phenomenon, existence of halo nevi, occurrence of 
spontaneous repigmentation, and amount of thyroid peroxidase antibodies. No associations appeared 
in whole vitiligo group. In subgroups, several allelic and haplotype associations were found. The 
strongest involved SNPs rs12301088 (near IL26 gene), that was associated with familial vitiligo and 
existence of halo nevi, and rs2257167 (IFNAR1 gene), that was associated with female vitiligo. 
Additionally, haplotypes consisting of rs12301088 and rs12321603 alleles (IL26-IL22 genes), that 
were associated with familial vitiligo and existence of halo nevi. In conclusion, several genetic 
associations with vitiligo subphenotypes were revealed and functional explanations to these remain to 
be determined in respective studies. 
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1. Introduction 
Vitiligo is a complex disease characterised by depigmented areas on the skin and hair which occur as a 
result of melanocyte destruction. The definite causes are yet to be established and may involve 
multiple genetic and environmental factors [1]. Still, among several hypotheses, the autoimmune 
theory has received the most support, with the autoinflammatory component of the disease gaining 
more attention recently [2-4]. For instance, increased levels of proinflammatory cytokines and 
receptors such as interleukin 6 (IL-6), IL-8, tumor necrosis factor α (TNF-α), and IL-2R have been 
measured in vitligo patients [5]. As to the genetic factors, estimates of vitiligo heritability range from 
16% to 46% in different populations. Overwhelming majority of nearly 90% of candidate genes 
encode immunoregulatory proteins and only 10% encode melanocyte proteins [6]. 
Our study focused on seven genetic regions of class II cytokine and their receptor genes. Specifically, 
interferon gamma (IFN-γ) that is primarily produced by natural killer (NK) cells, CD4+ and CD8+ T 
cells, and deviations in its expression have been associated with autoinflammatory and autoimmune 
diseases [7]. IL-26 is secreted by NK cells and T cells, and induces the production of IL-10, IL-8, and 
intercellular adhesion molecule 1 (ICAM-1) in epithelial cells [8, 9]. IL-22 is produced by variety of 
immune cells including different types of T cells, innate lymphoid cells (ILCs), NK cells, and 
dendritic cells [10]. Epithelial cells are the main targets of IL-22 and binding of this cytokine leads to 
induction of anti-microbial proteins, and also proliferative and anti-apoptotic pathways [11]. The 
corresponding genes IFNG, L26, and IL22 of these cytokines form a cluster at 12q15 chromosomal 
region. The functions of adjacently placed MDM1 gene are yet to be established, but the mRNA levels 
were increased in vitiligo skin and peripheral blood mononuclear cells (PBMCs) in our recent report 
[12]. Another group of cytokines are IL-28B, IL-28A and IL-29 (alternatively labeled IFN-λ3, IFN-λ2 
and IFN-λ1, respectively) encoded by gene cluster of IL28B, IL28A and IL29 in the 19q13.2 
chromosomal region. They can be expressed by almost any nucleated cell, especially dendritic cells, 
and induce anti-viral and anti-tumor pathways in a restricted population of target cells mainly 
comprised of epithelial cells and hepatocytes [13]. 
The receptors of class II cytokines are composed of two subunits which can be coupled alternatively. 
One cytokine can associate with more than one complex and a certain complex can bind more than one 
cytokine. IL-20R2 can be coupled with IL-20R1 to form a receptor for IL-19, IL-20 and IL-24, or with 
IL-22R1 to form a receptor for IL-19 and IL-20. IL-10R2 can be paired with IL-10R1 (IL-10 
receptor), IL-20R1 (IL-26 receptor), IL-22R1 (IL-22 receptor), and IL-28R1 (receptor for IL-28A, IL-
28B and IL-29). IFN-αR1 and IFN-αR2c complex binds IFN-α, -β, -ε, -κ, -ω, -δ, and –τ. IFN-γR1 and 
IFN-γR2 complex binds IFN-γ. In addition to these, IL-22R2 is a soluble protein that binds IL-22, 
serving as an antagonist of this cytokine. Single-nucleotide polymorphisms (SNPs) from the gene 
regions of all described receptor subunits except for IL-20R2 were selected for genotyping. Finally, 
tissue factor gene F3 was also included due to large degree of homology to these receptors [14]. 
The preceding gene expression studies had revealed substantial changes in many class II cytokine and 
receptor genes in vitiligo. Notably, IL22 expression was elevated in vitiligo patients along with one of 
its receptor subunits IL10RB [15]. A following study demonstrated changes in mRNA expression 
pattern of IL20RB, IL22RA2, IL28A, IL28B, IL28RA,MDM1, IFNA1, IFNB1, IFNG, and ICAM1 in 
skin and/or PBMCs of vitiligo patients [12]. Additionally, genetic associations were found with SNPs 
of IL19, IL20, and IL20RB genes [16]. Considering those findings, a genetic association study was 
designed with SNPs from the region of class II cytokine (IFNG, IL26, IL22, IL28B, IL28A, and IL29), 
their receptor (IL20RA, IL22RA1, IL10RA, IL10RB, IL28RA, IL22RA2, IFNAR1, IFNAR2, IFNGR1, 
and IFNGR2), receptor homolog (F3), and adjacently placed (MDM1) genes to be genotyped in 
Estonian case-control sample.  
 
2. Materials and Methods 
2. 1. Study sample 
Vitiligo patients (n = 109) and healthy control individuals (n = 328) were enrolled at the Department 
of Dermatology, University of Tartu, Estonia. All were unrelated, of Caucasian origin, and living in 
Estonia. Vitiligo diagnoses were based on characteristic skin depigmentation at typical locations and 
whiteness of skin lesions under Wood’s lamp. The patients were further divided into subgroups 
according to several characteristics. The patients were classified to have active vitiligo (n = 79) in case 
new areas of depigmentation had appeared during the previous 3 months and stable vitiligo (n = 30) if 
new areas or enlargement of previously existing depigmentation had not occurred. Early onset vitiligo 
(n = 33) was assigned in case the symptoms appeared before the age of 20 and late onset (n = 76) in 
case 20 or after. Female (n = 76) and male (n = 33) patients were analyzed separately with their 
respective controls (n = 182; n = 146) and also comparatively against each other. Familial vitiligo (n = 
26) was defined by occurrence of vitiligo in patients’ relatives and absence indicated the sporadic 
cases (n = 83). Two groups were formed according to the extent of affected areas: extent < 10% (n = 
54) and extent ≥ 10% (n = 55). Patients expressing the Köbner’s phenomenon, manifested by the 
development of new vitiligo patches at sites of skin injury comprised the Köbner+ group (n = 11) and 
those without it belonged to Köbner‒ (n = 98). The existence (n = 17) or absence (n = 92) of halo nevi 
was another differentiating factor. Patients displaying spontaneous repigmentation (n = 30) were 
analysed apart from the rest (n = 79). Finally, the amount of thyroid peroxidase antibodies (TPO-Ab) 
was determined by chemiluminescence immunoassay and used as a criterion for TPO-Ab<10 (n = 49) 
and TPO-Ab≥10 (n = 51) groups. 
The Ethics Committee of the University of Tartu approved the study and informed consent was 
obtained from all participants. 
  
2.2. SNP selection and genotyping 
SNPbrowser version 3.5 was used for SNP selection and SNPlexTM assay pool design. The inclusion 
of SNPs was based on density with spacing criterion around 10 kb, minor allele frequency cut-off 5%, 
and non-synonymous SNPs always preferred. Genomic DNA was extracted from 9 ml blood samples 
and Applied Biosystems SNPlexTM method was used for genotyping [17]. SNPlexTM platform 
utilises allele-specific hybridization probes and ensuing PCR to amplify the resulting products. Each 
amplicon contains a unique sequence that binds a specific fluorescent-labeled ZipChute probe. The 
latter are eventually separated and detected by capillary electrophoresis, enabling automatic allele 
calling by manufacturer provided software. 
 
2.3. Data analysis 
The Haploview v4.2 program was used for Hardy-Weinberg equilibrium (HWE) calculations in 
control group and also for allelic association and haplotype association tests between groups of 
patients and controls [18]. The Solid spine of LD algorithm integrated in Haploview v4.2 was applied 
to define the haplotype blocks and the resulting blocks were used in the haplotype association test. 
SNPs of each chromosome were analysed separately and rs3849301 was further separated from the 
rest of chromosome 1 SNPs due to the distance between them. Differences in allele or haplotype 
frequencies between cases and controls were assessed by chi square test. Null hypothesis was rejected 
when significant differences in allele or haplotype frequencies occurred and corresponding p values 
are presented in the text and tables. The statistical significance threshold was set to 0.05 for all tests. 
Ten thousand permutations were performed to correct p values for errors of multiple testing.  
 
3. Results 
A total of 30 SNPs selected from Class II cytokine and their receptor loci were genotyped (Table 1). 
All these SNPs met the inclusion criteria for minor allele frequency and Hardy-Weinberg equilibrium. 
 
3.1. Allelic association analysis 
A number of SNPs displayed significantly different allele frequencies among vitiligo patients 
compared to healthy control individuals. The results from whole vitiligo, early onset, late onset, 
familial, sporadic, extent<10%, extent≥10%, active, and stable vitiligo groups are shown in Table 2 
and significant associations from the remaining groups are described below in the following section. 
No associations were found when analyzing the whole vitiligo group, but several appeared in the 
subgroups. The most substantial results concerned the SNP rs12301088 in early onset (p = 0.0154, OR 
1.95, CI: 1.13 – 3.39), familial (p = 0.0048, OR 2.41, CI: 1.29 – 4.51), extent≥10% (p = 0.0138, OR 
1.7, CI: 1.11 – 2.61), and halo+ (p = 0.0033, OR 3.49, CI: 1.44 – 8.42) subgroups. Notably, the 
associations in familial and halo+ subgroups remained significant after correction for multiple testing 
(respective p values 0.0245 and 0.021). Also, rs2257167 produced a more convincing association in 
female vitiligo subgroup (p = 0.0020, OR 0.27, CI: 0.11 – 0.66), that withstood the correction for 
multiple testing (p = 0.0102), and additionally in familial vitiligo subgroup (p = 0.033, OR 0.15, CI: 
0.02 – 1.12). The rs1342642 association in stable vitiligo subgroup was one of the strongest revealed 
in this study (p = 0.0058, OR 0.26, CI: 0.09 – 0.72), but narrowly missed the statistical significance 
threshold after correction for multiple testing (p = 0.0777). The remaining SNP associations came 
from various subgroups and were weaker compared to those already described. Rs276586 was 
associated with sporadic (p = 0.0469, OR 1.44, CI: 1 – 2.1) and stable (p = 0.0325, OR 1.89, CI: 1.05 
– 3.42) vitiligo. Rs30461 was associated with early onset (p = 0.0278, OR 0.14, CI: 0.02 – 1.06) and 
female (p = 0.0384, OR 0.43, CI: 0.19 – 0.98) vitiligo. Rs2834117 was associated with sporadic (p = 
0.0354, OR 0.56, CI: 0.33 – 0.97), spontaneous repigmentation (p = 0.0221, OR 0.27, CI: 0.08 – 0.89), 
and TPO-Ab<10 (p = 0.0216, OR 0.4, CI: 0.18 – 0.9) vitiligo. Additionally, rs3795299 and rs276571 
were associated in Köbner+ subgroup (p = 0.0228, OR 2.76, CI: 1.11 – 6.87 and p = 0.0331 OR 0.34, 
CI: 0.12 – 0.96, respectively), rs7749054 and rs955155 in halo+ subgroup (p = 0.0484, OR 2.3, CI: 
0.98 – 5.38 and p = 0.0251, OR 2.41, CI: 1.09 – 5.32, respectively), rs2834167 and rs7282780 in 
familial vitiligo subgroup (p = 0.0378, OR 0.41, CI: 0.17 – 0.98 and p = 0.0175, OR 2.08, CI: 1.12 – 
3.85, respectively). 
When comparing allele frequencies among female patients against male patients, rs2257167 minor 
allele C was significantly more frequent among males (p = 0.0136, OR 3.65, CI: 1.23 – 10.77).   
 
 
3.2. Haplotype analysis 
Haplotype blocks were formed by SNPs of chromosome 1, 6, 12, 19, and 21. According to haplotype 
association analysis, the most significant differences in haplotype frequencies between patients and 
healthy controls occurred with Block 2 haplotypes CC and TC of chromosome 12 (harboring IL26-
IL22 genes). The results from this region in early onset, late onset, familial, sporadic, extent<10%, and 
extent≥10% groups are shown in Table 3 and significant associations from the remaining groups are 
described in the following section. These haplotypes were formed by alleles of rs12301088 and 
rs12321603, and the haplotype associations were evident in early onset (CC, p = 0.0249, OR 0.54, CI: 
0.31 –0.93; TC, p = 0.0123, OR 2, CI: 1.15 – 3.45), familial (CC, p = 0.008, OR 0.44, CI: 0.23 – 0.82; 
TC, p = 0.0038, OR 2.46, CI: 1.31 – 4.6), extent≥10% (CC, p = 0.0256, OR 0.62, CI: 0.4 – 0.95; TC, p 
= 0.0104, OR 1.74, CI: 1.14 – 2.66), and halo+ (CC, p = 0.0049, OR 0.3, CI: 0.12 – 0.73; TC, p = 
0.0027, OR 3.56, CI: 1.48 – 8.59) subgroups. The associations concerning TC in the last three 
subgroups and CC in halo+ subgroup remained significant after correction for multiple testing (p 
values 0.019, 0.0433, 0.0207, and 0.0251). The remaining haplotype associations involved various 
subgroups and none of those stayed significant when corrections for multiple testing were applied. 
Block 1 haplotype GC of chromosome 1 (IL22RA1) and Block 2 haplotype ACA of chromosome 6 
(IL22RA2) were associated in Köbner+ subgroup (p = 0.0175, OR 2.9, CI: 1.17 – 7.19 and p = 0.0243, 
OR 0.29, CI: 0.09 – 0.9, respectively). Block 1 haplotype CA of chromosome 6 (near IL20RA) was 
associated with sporadic (p = 0.0388, OR 1.45, CI: 1.02 – 2.07) and stable (p = 0.0213, OR 1.93, CI: 
1.09 – 3.41) vitiligo. Block 1 haplotype GG of chromosome 12 (near IFNG) was associated with halo+ 
(p = 0.0408, OR 2.61, CI: 1.01 – 6.78). Block 1 haplotype TT of chromosome 19 (IL28B) was 
associated with spontaneous repigmentation (p = 0.0319, OR 2, CI: 1.06 – 3.79) and TPO-Ab<10 (p = 
0.0176, OR 1.87, CI: 1.11 – 3.17) vitiligo. Additionally, Block 1 haplotype CT of chromosome 19 was 
associated in halo+ (p = 0.0433, OR 0.45, CI: 0.2 – 0.99) and Block 2 haplotype TC (IL29) in early 
onset (p = 0.201, OR 7.49, CI: 1.02 – 54.87) subgroup. 
When comparing haplotype frequencies among female patients against male patients, significant 
differences were found in three instances (Table 4). Block 1 haplotype CC of chromosome 1 
(IL22RA1) was more frequent among females (p = 0.0298, OR 2.99, CI: 1.07 – 8.38), whereas Block 1 
haplotype GGC of chromosome 12 (IFNG) and Block 1 haplotype TC of chromosome 21 (IFNAR1) 
were more frequent among males (p = 0.0297, OR 2.79, CI: 1.07 – 7.25; p = 0.0173, OR 3.51, CI: 1.18 
– 10.47). None of those three associations withstood the correction for multiple comparisons. 
 
4. Discussion 
In order to conduct genetic association analyses, 30 SNPs from class II cytokine and their receptor 
gene regions were genotyped in Estonian case-control sample. There were no associations in whole 
vitiligo group, but altogether 21 allelic and 20 haplotype associations were found in several subgroups. 
These occurred with SNPs from five out of seven studied genetic regions. The 1p23.3 locus that 
contained F3 gene and 11q23.3 locus that contained IL10RA gene did not contribute any statistical 
results. 
The first region under investigation was within 1p36.11 and contained cytokine receptor genes 
IL22RA1 and IL28RA. Genetic associations appeared in Köbner+ subgroup where G allele of 
rs3795299 and haplotype GC (composed of rs3795299 and rs16829204 alleles) were significantly 
more frequent among patients compared to controls. Secondly, alternative haplotype block composed 
of rs3934861 and rs3795299 was formed exclusively in male-female vitiligo comparative analysis and 
haplotype CC was significanlty more frequent in females. Two of these SNPs are situated in IL22RA1 
gene and are non-synonymous by function:  rs3795299 C/G alleles cause arginine/glycine substitution 
at position 518 and rs16829204 C/T alleles cause valine/isoleucine substitution at position 205 in the 
IL-22R1 peptide sequence. The IL-22R1 protein can be coupled with IL-10R2 to form a receptor for 
IL-22 or with IL-20R2 to form a receptor for IL-20 and IL-24. It is possible that the described genetic 
mutations cause changes in the formation of these receptors and/or alter their interactions with 
cytokines, but this cannot be further speculated. In addition, it has been demostrated, that IL-22R1 is a 
driver of inflammation in mice [19] and variants of IL22RA1 gene have been linked to common 
inflammatory disease chronic rhinosinusitis [20], which enhance the plausibility of its contribution to 
vitiligo pathogenesis. 
The SNPs of 6q23.3 region surrounded the genes IL20RA, IL22RA2 and IFNGR1. As a general 
remark, the 6q23.3 region has been indentified as a susceptibility region for rheumatoid arthritis [21, 
22], systemic lupus erythematosus [23] and multiple sclerosis [24]. Several allelic and haplotype 
associations were found. Non-synonymous SNP rs1342642C/T that causes leucine/phenylalanine 
substitution at position 382 in the IL-20R1 peptide sequence  was associated with stable vitiligo and 
the given result withstood the correction for multiple testing. The IL-20R1 protein can be coupled with 
IL-20R2 to form a receptor for IL-19, IL-20 and IL-24 or with IL-10R2 to form a receptor for IL-26. 
Interestingly, IL20RA mRNA expression was decreased in the skin of vitiligo patients in our previous 
study and especially among those with stable vitiligo [15]. This suggests that the C allele of rs1342642 
that was more frequent in stable vitligo group may be related to lower IL20RA mRNA levels in those 
patients. Moreover, the same allele was also significantly more frequent in psoriasis patients in our 
previous work [25]. The second associated SNP of this region was rs276586 in stable and sporadic 
vitiligo groups. It also formed a haplotype block with rs276526 and CA haplotypes of this block were 
significantly more frequent in those groups compared to controls. It was evident in our psoriasis 
genetic association study that both of these SNPs were in strong linkage disequilibrium with rs276504 
in the first intron of IL20RA gene [25] and thus these results may reflect changes in IL-20R1 
functioning. Our former vitiligo genetic association study involved SNPs rs1184860, rs1167846, and 
rs1167849 that are postioned between the two associated SNPs discussed above [16]. Nominal 
associations were found for rs1167849 and haplotypes CTA and CTG, although these did not remain 
significant after correction for multiple testing. The third significant SNP was rs276571 in Köbner+ 
group. Although it is an intergenic SNP, it belongs to the same haplotype block with rs719640 and 
rs276466, the last one being situated in IL22RA2 gene. Therefore, this association may be related to 
IL-22BP encoded by IL22RA2. Additionally, haplotype ACA of this block was significantly less 
frequent in Köbner+ vitiligo patients. IL-22BP is a soluble monomeric protein that binds IL-22, 
functioning as its antagonist. In our previous work, IL22RA2 mRNA was upregulated in uninvolved 
skin of vitiligo patients compared to involved and control skin [12]. Further analysis indicated a 
downregulation of IL22RA2 mRNA in involved skin of active vitiligio patients [12]. We have also 
demonstrated an upregulated state of proinflammatory IL-22 in vitiligo patients [15]. Taken together, 
these findings suggested substantial changes in IL-22 signaling in vitiligo and the presently described 
mutations may have an effect of this. The fourth associated SNP was rs7749054 in patients 
manifesting halo nevi. This SNP in positioned between IL22RA2 and IFNGR1. The latter gene 
encodes IFN-γR1, a ligand-binding chain of the receptor for inflammation promoting cytokine IFN-γ.  
Notably, polymorphisms in IFNGR1 have been associated with allergic diseases [26] and systemic 
lupus erythematosus [27].  
The SNPs of 12q15 region were near the genes IFNG, IL26, IL22, and MDM1. This gene cluster has 
been associated with chronic inflammatory diseases including rheumatoid arthritis, type I diabetes, 
ulcerative colitis, and asthma [28-31]. The single associated SNP stood out from the rest, namely 
rs12301088 that produced significantly differing allelic frequencies in early onset, familial, extent ≥ 
10%, and halo+ groups. Secondly, haplotypes CC and TC of Block 2 that involved alleles of this SNP 
and rs12321603 were associated in the same groups. Results in familial and halo+ groups also 
withstood the correction for multiple testing. None of the four studied SNPs were in the gene coding 
regions. Since all the above described statistical results came from Block 2, they can be mainly related 
to IL26, IL22, and MDM1 genes that fall in the range of this haplotype block. Only one result involved 
Block 1 (rs10784680 and rs10878763), when haplotype GG was associated in halo+ group. 
Exceptional to this was male-female vitiligo comparative analysis, where rs1078468, rs10878763, and 
rs12301088 were grouped into a haplotype block. The revealed association of haplotype GGC points 
to IFNG gene enclosed in this block. Still, in some of the other groups all four SNPs were included in 
a single haplotype block, but no haplotype associations occurred in those cases. The expression of 
MDM1 and all three cytokine genes of this cluster has been measured in vitiligo patients in the course 
of our previous studies. IFNG mRNA expression was increased in vitiligo involved skin and in 
PBMCs of the patients [12]. IL26 levels in skin did not differ between patients and controls [12]. IL22 
was upregulated on mRNA level in PBMCs and on protein level in the sera of the patients [15]. 
MDM1 mRNA expression was increased in vitiligo skin and in PBMCs [12]. Together, those findings 
suggested an active role for IFN-γ, IL-22, and MDM1 in vitiligo pathogenesis. The significant SNPs 
of this study do not directly affect the amino acid composition of these proteins but may be in linkage 
disequilibrium with the polymorphisms that do or with the ones that are involved in gene regulation. 
The SNPs of 19q13.2 region were in the area of IL28B, IL28A, and IL29 genes. Together they 
constitute interferon type III family and signal through a common receptor that is composed of IL-
10R2 and IL-28R1. In our analysis, allelic associations were revealed for two SNPs: rs955155 was 
associated in patients manifesting halo nevi and rs30461 was associated with early onset and female 
vitiligo. In addition, Block 1 (alleles of rs955155 and rs10853727) halplotype CT was associated with 
halo nevi and haplotype TT was associated with spontaneous  repigmentation and TPO-Ab<10. Block 
2 (alleles of rs30461 and rs12972575) haplotype TC was associated with early onset vitiligo. The 
results concerning rs955155 and Block 1 haplotypes could be primarily related to IL28B that is 
situated within that haplotype block.  Remarkably, polymorphisms near IL28B gene have been 
repeatedly associated with hepatitis C virus treatment response and clearance [32] and lately also with 
allergic disease [33]. The results concerning rs30461 and Block 2 haplotype are inclined towards IL29, 
since rs30461T/C is a non-synonymous SNP that causes asparagine/aspartate substitution at position 
188 in IL-29 peptide.  The same SNP has been associated with psoriasis  in Russian [34] and Estonian 
(unpublished data) populations. Similarly to this study, the C allele was more prevalent among 
controls in both instances. With regard to expression, IL28B mRNA was found to be elevated and 
IL28A mRNA downregulated in vitligo patients PBMCs [12]. 
The SNPs of 21q22.11 region were in the area of IFNAR2, IL10RB, IFNAR1, and IFNGR2 genes. 
Earlier investigations have yielded genetic associations with various immune-related diseases from 
this region:  multiple sclerosis [35], systemic sclerosis [36], graft-versus-host disease [37], systemic 
lupus erythematosus [38], and asthma [39]. Several allelic associations were found. Rs2834117 was 
associated with vitligo sporadic form, spontaneous repigmentation, and TPO-Ab<10. Interestingly, 
three associations appeared in familial vitiligo group with SNPs  rs2834167, rs7282780, and 
rs2257167. The latter SNP was also associated with female vitiligo and displayed significantly 
different allele frequencies when comparing female patients to male patients. The result in female 
vitiligo group remained significant when correcting for multiple testing. Lastly, in male-female vitiligo 
comparative analysis, haplotype TC comprising rs7282780 and rs2257167 alleles was significantly 
more frequent among males. Rs2834167A/G is a non-synonymous SNP that causes lysine/glutamate 
substitution at postition 47 in IL-10R2 peptide. The A allele was more common in familial vitiligo 
group, which was also apparent in patients of systemic sclerosis [36] and systemic lupus 
erythematosus [38] studies. Further, the respective IL10RB mRNA had unchanged expression in 
vitiligo skin, but was upregulated in patients PBMCs [15]. Rs2257167G/C is a non-synonymous SNP 
that causes valine/leucine substitution at position 168 in IFNAR1 peptide. Again, the definite 
functional roles of associated SNPs can not be asserted. Changes in IFNAR1 and IFNAR2 functions 
could affect type I interferon signaling i.e. IFN-α, IFN-β and, IFN-ω. Changes in IL10RB could affect 
IL-10, IL-22, IFN-λ, and IL-26 signaling. Finally, changes in IFNGR2 could affect proinflammatory 
action of IFN-γ. 
To conclude, the present genetic association study did not find any SNPs to be associated with general 
vitiligo diagnosis. However, many SNP allele and haplotype frequencies differed significantly from 
controls when analyzing specific vitiligo subgroups that were defined according to additional 
characteristics of their phenotypes. The strongest associations were evident for SNPs rs12301088 
(near IL26) and rs2257167 (IFNAR1), and haplotypes  that consisted of rs12301088 and rs12321603 
alleles (IL26-IL22). These results support the suggested role of class II cytokines in vitiligo 
pathogenesis and remain to be verified in replication genetic studies and functional studies.  
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Tables 
 
Table 1. Characteristics of studied SNPs 
SNP 
Chr 
region 
Base Position Gene 
Major/minor 
alleles 
Function MAF 
rs3934861 1p36.11 24304543 MYOM3 T/C intron 0.448 
rs3795299 1p36.11 24320055 IL22RA1 C/G R518G 0.349 
rs16829204 1p36.11 24327275 IL22RA1 C/T V205I 0.184 
rs1416834 1p36.11 24359247 IL28RA 
IL28RA 
A/G intron 0.359 
       
rs3849301 1p21.3 94750787 ABCD3 G/A intron 0.127 
       
rs4896227 6q23.3 137341703  C/T intergenic 0.274 
rs1342642 6q23.3 137364906 IL20RA C/T L382F 0.251 
rs276586 6q23.3 137417095  A/C intergenic 0.48 
rs276526 6q23.3 137432224  G/A intergenic 0.489 
rs276571 6q23.3 137468286  G/A intergenic 0.479 
rs719640 6q23.3 137484439  T/C intergenic 0.479 
rs276466 6q23.3 137508307 IL22RA2 
IL22RA2 
A/G 3’UTR 0.197 
rs7749054 6q23.3 137542479  T/G intergenic 0.151 
rs1343677 6q23.3 137625487  T/C intergenic 0.422 
rs12197182 6q23.3 137675944  G/A intergenic 0.129 
       
rs3135932 11q23.3 117369273 IL10RA A/G S159G 0.181 
       
rs10784680 12q15 66814383  G/A intergenic 0.049 
rs10878763 12q15 66829965  G/T intergenic 0.37 
rs12301088 12q15 66876215  C/T intergenic 0.449 
rs12321603 12q15 66973117 MDM1 C/T 3’ near gene 0.013 
       
rs955155 19q13.2 44421319  C/T intergenic 0.263 
rs10853727 19q13.2 44432303  T/C intergenic 0.105 
rs30461 19q13.2 44480955 IL29 T/C N188D 0.098 
rs12972575 19q13.2 44548086 SAMD4B C/T intron 0.045 
       
rs2834117 21q22.11 33464020 C21orf54 G/A intron 0.198 
rs2834133 21q22.11 33485037  T/C intergenic 0.471 
rs2300370 21q22.11 33526427 IFNAR2 
IFNAR2 
G/A intron 0.319 
rs2834167 21q22.11 33562658 IL10RB A/G K47E 0.261 
rs7282780 21q22.11 33609224  T/A intergenic 0.311 
rs2257167 21q22.11 33637569 IFNAR1 G/C V168L 0.116 
 
MAF – minor allele frequency among vitiligo patients and healthy controls. 
 
 
 
Table 2. Results of allelic association analysis 
 
Only SNPs that were associated in at least one of these groups are presented 
P value ≤ 0.05 bolded 
* P value ≤ 0.05 after 10 000 permutations 
 
 
 
 
 
 
 
 
SNP Gene Control 
MAF 
Vitiligo Early onset Late onset Familial Sporadic Extent<10% Extent≥10% Active Stable 
MAF P value MAF P value MAF P value MAF P value MAF P value MAF P value MAF P value MAF P value MAF P value 
rs1342642 IL20RA 0.262 0.213 0.1714 0.268 0.9258 0.189 0.0795 0.19 0.3041 0.219 0.2835 0.229 0.492 0.196 0.1714 0.257 0.9033 0.083 0.0058 
rs276586  0.463 0.536 0.0754 0.552 0.1955 0.529 0.1602 0.477 0.8547 0.553 0.0469 0.562 0.0693 0.51 0.3844 0.507 0.3414 0.62 0.0325 
rs12301088  0.438 0.485 0.2499 0.603 0.0154 0.435 0.9502 0.652 0.0048* 0.433 0.923 0.396 0.4414 0.57 0.0138 0.486 0.2933 0.481 0.5483 
rs30461 IL29 0.108 0.063 0.0683 0.017 0.0278 0.083 0.3991 0.023 0.0714 0.075 0.2406 0.076 0.3496 0.051 0.081 0.077 0.2791 0.021 0.0544 
rs2834117 C21orf54 0.212 0.149 0.0703 0.12 0.1227 0.161 0.2113 0.211 0.9882 0.131 0.0354 0.143 0.1421 0.155 0.2261 0.167 0.2542 0.095 0.0703 
rs2834167 IL10RB 0.27 0.232 0.2975 0.217 0.3742 0.239 0.4615 0.13 0.0378 0.263 0.87 0.23 0.4036 0.235 0.4657 0.236 0.41 0.222 0.4488 
rs7282780  0.305 0.33 0.5173 0.397 0.1496 0.3 0.9132 0.477 0.0175 0.285 0.6355 0.298 0.8912 0.362 0.2676 0.321 0.7009 0.354 0.4759 
rs2257167 IFNAR1 0.128 0.079 0.0661 0.054 0.1036 0.09 0.2181 0.022 0.033 0.097 0.3122 0.096 0.3785 0.062 0.0659 0.077 0.0939 0.083 0.3686 
  
Table 3. Results of chromosome 12 haplotype analysis 
Haplotype 
block 
rs12301088 rs12321603 
Controls Early onset Late onset Familial Sporadic Extent<10% Extent≥10% 
Freq. Freq. P value Freq. P value Freq. P value Freq. P value Freq. P value Freq. P value 
Block 1 G G 0.588 0.644 0.407 0.536 0.2714 0.687 0.1858 0.532 0.2145 0.529 0.2762 0.607 0.7181 
(near IFNG) G T 0.360 0.339 0.7544 0.413 0.242 0.269 0.2175 0.428 0.1196 0.430 0.186 0.353 0.9003 
 A G 0.049 0.015 0.242 0.050 0.9966 0.041 0.8064 0.039 0.5825 0.041 0.7048 0.039 0.6329 
                
Block 2 C C 0.550 0.397 0.0249 0.565 0.7502 0.348 0.0080 0.567 0.7179 0.604 0.3236 0.430 0.0256 
(IL26-IL22) T C 0.432 0.603 0.0123 0.435 0.9563 0.652 0.0038* 0.433 0.9803 0.396 0.5032 0.570 0.0104* 
 C T 0.017 0.000 0.3108 0.000 0.1184 0.000 0.3666 0.000 0.1036 0.000 0.1925 0.000 0.1835 
 
P value ≤ 0.05 bolded 
* P value ≤ 0.05 after 10 000 permutations 
 
 
 
 
Table 4. Female and male vitiligo comparative haplotype association analysis 
 
P value ≤ 0.05 bolded 
 
 
 
 
 
 
Chromosome 
Haplotype 
Block 
Haplotype 
Female 
freq. 
Male 
freq. 
P 
value 
Chr1 Block 1 rs3934861 rs3795299      
 (IL22RA1) T C   0.478 0.538 0.4357 
  C G   0.275 0.322 0.5072 
  C C   0.203 0.078 0.0298 
  T G   0.044 0.062 0.5902 
         
Chr6 Block 1 rs276586 rs276526      
 (near IL20RA) C A   0.491 0.566 0.3341 
  A G   0.470 0.399 0.3552 
  C G   0.024 0.018 0.8022 
  A A   0.015 0.018 0.9136 
 Block 2 rs276571 rs719640 rs276466 rs7749054    
 (IL22RA2) A C A T 0.398 0.389 0.9048 
  G T A T 0.243 0.244 0.9889 
  G T G T 0.174 0.113 0.2733 
  G T A G 0.141 0.160 0.7261 
  A C G T 0.032 0.054 0.4686 
  A C A G 0.012 0.024 0.5255 
         
Chr12 Block 1 rs10784680 rs10878763 rs12301088     
 (IFNG) G G T  0.499 0.432 0.3934 
  G T C  0.389 0.350 0.6014 
  G G C  0.067 0.167 0.0297 
  A G C  0.044 0.033 0.7251 
         
Chr21 Block 1 rs7282780 rs2257167      
 (IFNAR1) T G   0.601 0.578 0.7641 
  A G   0.352 0.272 0.2742 
  T C   0.045 0.144 0.0173 
